The Effect And Safety Of Bleomycin And IL-2in The Treatment Of Malignant Pleural Effusion

Purpose: To evaluate the efficacy of Bleomycin combined interleukin-2intreatment for malignant pleural effusion by observing the efficiency andsafety of central venous catheter and intrapleural injection of bleomycincombined interleukin-2therapy of malignant pleural effusion.Methods:106patients with malignant pleural effusion were divided into three groups，Malignant pleural effusions were excreted cleanly fromindwelling chest tube. Group A were treated with intrapleural infusion of bleomyein1mg/kg,saline50ml,2%lidocaine200mg, Group B with Intrathoracic injection of interleukin-2two Million U, saline50ml,2%lid-ocaine200mg,Group C with Intrathoracic injection of bleomyein1mg/kg,interleukin-2two Million U,saline50ml,2%lidocaine200mg. then envelo-ping tube for24h,and Draining for5-7days, dosing again3-4times,assessing the condition after one month.30ml pleural effusion was respec-tively specimened before injection and injection4times later, Determination of carcinoembryonic antigen, cytokeratin19fragment, neuron-specific enolase levels were assessed by immune particle electroluminescence, evaluating the efficacy after one month. Results: Group A total effective rate was63.3%, group B64.7%, group C85.7%. group C was significantly higher than A, group B (P <0.05), nosignificant difference between group A and group B. KPS scoreimprovement rate of group A is63.3%, group B64.7%, group C85.7%, Thethree groups showed significant improvement, group C was significantlygreater than the improvement in group A and group B (P <0.05). About themid-progression free survival(mPFS)，A is3.7months,B is2.4months,C is4.4months，About the median overrall survival,A is10.5months,B is7.8months，C is12.5months，there have no statistics enaymology mean betweenthe three groups.The CEA, CYFRA21-1levels were decreased in the threegroups, no significant difference in the three groups. Adverse reactions, a fewcases emerged low fever, chest pain, gastrointestinal reactions, group Aincidence was13.3%,group B5.9%, group C4.7%. groupA、 B and group Chas no significant difference.Conclusion: Intrathoracic injection of bleomycin combined interleukin-2control pleural effusion effectively,with mild adverse reactions, improvingsymptoms and quality Of life.